5th Annual Novel Conjugates Summit

Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as well as the exploration of non-oncology indications.

The 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored, what benefit each approach has and the directions the space is heading.

Attendees gain valuable competitive insight into emerging technologies, early data, and the rationale behind each approach, from established pharma leaders to the newest biotech entrants. Whether your goal is to benchmark your pipeline, explore partnership opportunities, or stay ahead of fast-moving design trends, this summit offers a front-row seat to the next wave of conjugate innovation.

View the program: https://ter.li/m5sjll